ATE451466T1 - Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält - Google Patents

Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält

Info

Publication number
ATE451466T1
ATE451466T1 AT98963811T AT98963811T ATE451466T1 AT E451466 T1 ATE451466 T1 AT E451466T1 AT 98963811 T AT98963811 T AT 98963811T AT 98963811 T AT98963811 T AT 98963811T AT E451466 T1 ATE451466 T1 AT E451466T1
Authority
AT
Austria
Prior art keywords
heterologue
fusion protein
recombinant rhabdovirus
rhabdovirus containing
recombinant
Prior art date
Application number
AT98963811T
Other languages
German (de)
English (en)
Inventor
Michael A Whitt
Clinton Robison
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Application granted granted Critical
Publication of ATE451466T1 publication Critical patent/ATE451466T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20211Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20211Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98963811T 1997-12-22 1998-12-22 Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält ATE451466T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6847297P 1997-12-22 1997-12-22
PCT/US1998/026084 WO1999032648A1 (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein

Publications (1)

Publication Number Publication Date
ATE451466T1 true ATE451466T1 (de) 2009-12-15

Family

ID=22082797

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963811T ATE451466T1 (de) 1997-12-22 1998-12-22 Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält

Country Status (14)

Country Link
US (2) US6497873B1 (enExample)
EP (1) EP1040198B1 (enExample)
JP (1) JP4544497B2 (enExample)
AP (1) AP1968A (enExample)
AT (1) ATE451466T1 (enExample)
AU (2) AU752004B2 (enExample)
BR (1) BR9814370A (enExample)
CA (1) CA2316033A1 (enExample)
DE (1) DE69841372D1 (enExample)
IL (2) IL136905A0 (enExample)
MX (1) MXPA00006184A (enExample)
NZ (1) NZ505312A (enExample)
OA (1) OA11432A (enExample)
WO (1) WO1999032648A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260057T3 (es) * 1999-09-17 2006-11-01 Wellstat Biologics Corporation Virus oncolitico.
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
JP2004537279A (ja) * 2001-03-09 2004-12-16 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 感染性c型肝炎ウイルス合成のための細胞培養システム
US20030044386A1 (en) * 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
EP2039773B1 (en) 2003-03-27 2011-12-28 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and use thereof
US7541038B2 (en) * 2003-06-05 2009-06-02 Wyeth Holdings Corporation Fusogenic, self-propagating blebs as immunogenic compositions
AU2004250129A1 (en) 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded RNA viruses from cDNA
ES2741138T3 (es) * 2006-09-15 2020-02-10 Childrens Hospital Of Eastern Ontario Res Institute Inc Rhabdovirus oncolítico de Farmington
WO2009014878A2 (en) * 2007-07-06 2009-01-29 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
EP2398496B1 (en) * 2009-02-20 2015-08-05 International AIDS Vaccine Initiative Vesicular stomatitis virus vectors encoding hiv env epitopes
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2013158263A1 (en) * 2012-04-18 2013-10-24 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
JP2020518275A (ja) * 2017-05-03 2020-06-25 バイオマリン ファーマシューティカル インコーポレイテッド 造血幹細胞の形質導入のための改善されたレンチウイルス
KR102839445B1 (ko) 2017-05-10 2025-07-28 파마 싱크, 엘엘씨 암 치료용 보체 불활성화 내성의 외피 바이러스
WO2021158878A1 (en) * 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides useful for detecting anti-rhabdovirus antibodies
CN116144608A (zh) * 2021-09-29 2023-05-23 上海行深生物科技有限公司 病毒培养方法

Also Published As

Publication number Publication date
EP1040198B1 (en) 2009-12-09
BR9814370A (pt) 2000-10-10
AP2000001852A0 (en) 2000-06-30
OA11432A (en) 2004-04-26
JP4544497B2 (ja) 2010-09-15
JP2001526901A (ja) 2001-12-25
DE69841372D1 (de) 2010-01-21
EP1040198A1 (en) 2000-10-04
IL136905A (en) 2007-10-31
AU1905699A (en) 1999-07-12
AU2002300207B2 (en) 2006-07-13
AP1968A (en) 2009-04-30
WO1999032648A1 (en) 1999-07-01
AU752004B2 (en) 2002-09-05
US6497873B1 (en) 2002-12-24
US20030138457A1 (en) 2003-07-24
IL136905A0 (en) 2001-06-14
MXPA00006184A (es) 2003-02-11
NZ505312A (en) 2003-01-31
CA2316033A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
ATE451466T1 (de) Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält
GB9718609D0 (en) Fusion protein
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
AU7274898A (en) Recombinant antibody-enzyme fusion proteins
DE69839603D1 (de) Zierenden proteins
NO2006014I1 (no) Insulin glulisin
NO2010013I1 (no) Rekombinant FSH-CTP
FI20002013L (fi) HCV-fuusioproteiini
IS5375A (is) KAY-nýstárlegt ónæmisprótín
AU2002300207A1 (en) Recombinant Rhabdovirus containing a heterologous Fusion Protein
NO993901D0 (no) Bisykliske aminosyrer
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
GB9913437D0 (en) Fusion proteins
EE04001B1 (et) Peptiidne farmatseutiline kompositsioon
MX9909801A (es) Metodo para separar proteinas de fusion
AU9798398A (en) Gfp-annexin fusion proteins
DE69931010D1 (de) Peptide mit osteogener Aktivität
DE69938579D1 (de) Extrazelluläre Matrixproteine mit modifizierten Aminosäuren
NO20021275D0 (no) Transgent produserte fusjonsproteiner
DE69705017D1 (de) Medikamente bindendes Protein
IL135942A0 (en) Assay employing cadc fusion proteins
DE69823225D1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
BR9811344B1 (pt) mÉtodo para aumentar a expressço de proteÍna exàgena.
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
DK0862197T3 (da) Sikringsstik

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties